iShares Biotechnology ETF
608 hedge funds and large institutions have $5.68B invested in iShares Biotechnology ETF in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 204 increasing their positions, 227 reducing their positions, and 77 closing their positions.
4.44% more ownership
Funds ownership: 58.57% → 63.02% (+4.4%)
0% less capital invested
Capital invested by funds: $5.69B → $5.68B (-$13.3M)
3% less funds holding
Funds holding: 624 → 608 (-16)
10% less repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 227
14% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 77
17% less funds holding in top 10
Funds holding in top 10: 30 → 25 (-5)
43% less call options, than puts
Call options by funds: $377M | Put options by funds: $657M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$464M |
| 2 |
N
Natixis
Paris,
France
|
+$110M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$45.1M |
| 4 |
JG
Jefferies Group
New York
|
+$38.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$29.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Churchill Management
Los Angeles,
California
|
-$192M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$130M |
| 3 |
Goldman Sachs
New York
|
-$69.3M |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$47.6M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$43.7M |
IBB Hedge Fund Activity: Q1 2018 in Review
608 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2018, worth a combined $5.68B — down 0.23% from $5.69B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of IBB and 66 opened new positions — a net loss of 11 holders — while 227 trimmed existing stakes and 204 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $464M. The largest seller was Churchill Management, exiting entirely with an estimated $192M sold.
- 608 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2018, down from 624 in Q4 2017.
- Funds reported $5.68B of iShares Biotechnology ETF stock for Q1 2018, down 0.23% quarter-over-quarter.
- 66 funds opened new iShares Biotechnology ETF positions in Q1 2018 and 77 closed out, a net change of -11 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2018 was Deutsche Bank, an estimated $464M added.
- The largest iShares Biotechnology ETF seller in Q1 2018 was Churchill Management, an estimated $192M sold.
Based on aggregated 13F filings for Q1 2018.